SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:Aerocrine AB (STO:AERO-B), the innovator of NIOX® brand medical devices announces today a collaboration with Microsoft. Aerocrine’s devices are used by physicians to measure Fractional exhaled Nitric Oxide (FeNO), a biomarker for allergic, airway inflammation which is linked with Asthma. The collaboration will utilize Microsoft’s secure cloud services to transmit device telemetry data from physician and company sites in Sweden, UK and US back to Aerocrine for analyses. Aerocrine’s goal is to use this information to deploy its field resources for customer service and sales support in the future. Microsoft chose Aerocrine due to its device technology, global reach and commitment to progressing human health management.
Help employers find you! Check out all the jobs and post your resume.
